

SHL/SEC/2023

November 09, 2023

The Bombay Stock Exchange Limited
Listing Department,
1st Floor, New Trading Ring,
Rotunda Building,
Phiroze JeeJeeBhoy Towers, Dalal Street, Fort
Mumbai – 400 001.
Company Code: 537253

The Calcutta Stock Exchange Ltd.
7, Lyons Range
Kolkata - 700 001 India

Dear Sir,

Sub. : **Outcome of the 256th Board Meeting held on 09.11.2023**

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are pleased to inform, inter-alia the outcome of the Meeting of the Board of Directors of the Company held on Thursday, November 09, 2023, at 3:35 p.m. The Board meeting was **concluded at 5:28 p.m.**

1. Approved Un-Audited Financial Results (standalone and consolidated) for the 2nd quarter/ 1st half year ended September 30, 2023. (Copy enclosed)
2. Based on the recommendation of the Nomination and Remuneration Committee, approved and recommended for re-appointment of Dr. Harish Pal Kumar (DIN: 01826010) as Non-executive & Independent Director of the Company by shareholders of the Company by passing special resolution through postal ballot.

Details of the information as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed herewith as **Annexure-1**

3. Based on the recommendation of the Nomination and Remuneration Committee, approved and recommended for re-appointment of Mr. Bejon Kumar Misra (DIN: 01015633) as Non-executive & Independent Director of the Company by shareholders of the Company by passing special resolution through postal ballot.

Details of the information as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed herewith as **Annexure-2**

4. Accorded the approval for postal Ballot Notice for seeking consent of the members of the Company for certain special Businesses viz. re-appointment of Dr. Harish Pal Kumar (DIN: 01826010) as Non-executive & Independent Director of the Company and re-appointment of Mr. Bejon Kumar Misra (DIN: 01015633) as Non-executive & Independent Director of the Company.

Postal Ballot Notice along with Explanatory statement shall be issued/sent to the members and will be simultaneously intimated/submitted to the stock exchanges where the shares of the Company are listed.

You are requested to take the above information in your record and oblige us.


Thanking you,

Yours sincerely,

for **Sunil Healthcare Limited**


Satyendu Pattnaik
Company Secretary & Compliance Officer
FCS-7736
Encl a/a






SUNIL HEALTHCARE LIMITED
Registered Office
 38E/252-A, Vijay Tower, Shahpurjat
 New Delhi-110049
 Email: info@sunilhealthcare.com; website: www.sunilhealthcare.com
 CIN : L24302DL1973PLC189662

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2023


Particulars	Standalone						Year Ended Standalone 31st March 2023	Consolidated						Rs. in Lakhs
	Quarter ended		Half Year Ended		30th September 2022	30th September 2022		Quarter ended		Half Year Ended		30th September 2022	30th September 2022	Year Ended Consolidated
	30th September 2023	30th June 2023	30th September 2022	30th September 2023				30th September 2023	30th September 2023	30th June 2023	30th September 2022			30th September 2023
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1 Revenue from Operations	2,357.65	2,213.23	3,178.02	4,570.88	6,586.13	11,182.95	2,370.16	2,250.95	3,064.06	4,621.11	6,404.65	11,049.10		
2 Other Income	33.14	81.60	57.63	114.74	91.16	162.92	21.97	118.81	177.18	140.78	268.91	449.64		
3 Total Income (1+2)	2,390.79	2,294.83	3,235.65	4,685.62	6,677.29	11,345.87	2,392.13	2,369.76	3,241.24	4,761.89	6,673.56	11,498.74		
4 Expenses														
a) Cost of Materials consumed	1,229.73	1,223.18	1,362.09	2,452.91	2,615.09	4,984.14	1,229.73	1,223.18	1,362.09	2,452.91	2,615.09	4,984.14		
b) Purchase of Stock-in-trade	0.94	-	1.36	0.94	1.59	16.83	0.94	-	1.36	0.94	1.59	16.83		
b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(18.91)	(89.96)	(126.78)	(108.87)	(218.10)	(327.71)	(27.40)	(72.93)	(151.40)	(100.33)	(265.11)	(279.67)		
c) Employees benefit expenses	333.81	324.45	419.35	658.26	809.51	1,477.71	333.81	324.45	419.35	658.26	809.51	1,477.71		
d) Finance Costs	131.25	126.64	110.04	257.89	191.92	416.75	131.25	126.64	110.04	257.89	191.92	416.75		
e) Depreciation and amortisation	159.26	160.78	170.89	320.04	333.92	701.00	159.31	160.83	170.93	320.14	334.00	701.18		
f) Other Expenses	693.27	648.34	983.54	1,341.61	2,018.20	3,101.29	710.62	694.48	1,025.33	1,405.10	2,100.59	3,233.47		
Total Expenses	2,529.35	2,393.43	2,920.49	4,922.78	5,752.13	10,370.01	2,538.26	2,456.65	2,937.70	4,994.91	5,787.59	10,550.41		
5 Profit before tax (3-4)	(138.56)	(98.60)	315.16	(237.16)	925.16	975.86	(146.13)	(85.89)	303.54	(233.02)	885.97	948.33		
6 Tax Expenses (Net)	(36.55)	(22.99)	90.26	(59.54)	253.51	278.17	(36.24)	(22.72)	90.89	(58.96)	254.82	280.12		
a) Current Tax	-	-	63.88	-	165.70	167.49	0.31	0.27	64.51	0.58	167.01	169.44		
ii)-Tax for Earlier Period	-	-	-	-	-	-	-	-	-	-	-	-		
b) Deferred Tax Charged/(Credit)	(36.55)	(22.99)	26.38	(59.54)	87.81	110.68	(36.55)	(22.99)	26.38	(59.54)	87.81	110.68		
7 Profit/(loss) after tax	(102.01)	(75.61)	224.90	(177.62)	671.65	697.69	(109.89)	(64.17)	212.65	(174.06)	631.15	668.21		
8 Other Comprehensive Income (OCI)	-	-	-	-	-	(4.11)	2.29	(20.26)	(8.62)	(17.97)	(19.74)	(4.11)		
a) Items that will not be reclassified to Profit or Loss (net of tax)	-	-	-	-	-	(4.11)	-	-	-	-	-	(4.11)		
b) Items that will be reclassified to Profit or Loss (net of tax)	-	-	-	-	-	-	2.29	(20.26)	(8.62)	(17.97)	(19.74)	(59.90)		
9 Total Comprehensive Income	(102.01)	(75.61)	224.90	(177.62)	671.65	693.58	(107.60)	(84.43)	204.03	(192.03)	611.41	604.20		
10 Paid-up equity share capital (Face value per share Rs.10/-)	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48		
11 Other Equity	-	-	-	-	-	5,147.07	-	-	-	-	-	4,574.21		
12 Earning per share of Rs.10/- each(not annualised)														
(a) Basic (Rs.)	(0.99)	(0.74)	2.19	(1.73)	6.55	6.80	(1.07)	(0.63)	2.07	(1.70)	6.15	6.52		
(b) Diluted (Rs.)	(0.99)	(0.74)	2.19	(1.73)	6.55	6.80	(1.07)	(0.63)	2.07	(1.70)	6.15	6.52		



Rs. in Lakhs

2 Particulars		Standalone		Consolidated	
		As at 30th Sep. 2023	As at 31st March 2023	As at 30th Sep. 2023	As at 31st March 2023
		Un-audited	Audited	Un-audited	Audited
A ASSETS					
1 Non Current Assets					
(a) Fixed Assets					
(i) Property, Plant and Equipment					
	5,192.78	5,473.07	5,192.95	5,473.33	
(ii) Capital Work-in-Progress					
	3.30	0.72	3.30	0.72	
(iii) Right of Use Assets					
	1,500.44	1,557.63	1,500.44	1,557.63	
(iv) Other Intangible Assets					
	10.11	12.27	10.11	12.27	
(b) Financial Assets					
(i) Investment					
	0.10	0.10	-	-	
(ii) Other financial assets					
	199.37	199.37	199.37	199.37	
(c) Other non-current Assets					
	99.16	25.03	99.16	25.03	
2 Current Assets					
(a) Inventories					
	1,591.60	1,245.72	1,711.13	1,360.43	
(b) Financial Assets					
(i) Trade Receivables					
	4,438.31	3,550.68	3,751.36	2,841.04	
(ii) Cash and Cash Equivalents					
	1.77	1.58	3.57	58.67	
(iii) Other Bank Balances					
	334.93	334.93	334.93	334.93	
(iv) Other Financial Assets					
	73.25	54.90	44.85	26.74	
(c) Current Tax Assets					
	-	-	-	-	
(d) Other Current Assets					
	221.73	151.45	285.77	188.87	
TOTAL ASEESTS					
	13,666.85	12,607.45	13,136.96	12,079.03	
B EQUITY AND LIABILITIES					
1 Equity					
(a) Equity Share Capital					
	1,025.48	1,025.48	1,025.48	1,025.48	
(b) Other Equity					
	4,969.45	5,147.07	4,382.19	4,574.21	
2 Non Current Liabilities					
(a) Financial Liabilities-					
(i) Borrowings					
	1,744.75	901.38	1,744.75	901.38	
(ii) Lease Liability					
	50.45	79.25	50.45	79.25	
(b) Provisions					
	122.79	160.46	122.79	160.46	
(c) Deferred Tax Liabilities (Net)					
	730.24	789.79	730.24	789.79	
3 Current Liabilities					
(a) Financial Liabilities					
(i) Borrowings					
	3,037.72	2,620.04	3,037.72	2,620.04	
(ii) Trade Payables					
Total Outstanding dues of Micro enterprises and small enterprises					
	187.76	143.35	187.76	143.35	
Total Outstanding dues of Creditors other than Micro enterprises and small enterprises					
	1,300.78	1,295.09	1,345.18	1,331.79	
(iii) Lease Liabilities					
	66.62	78.23	66.62	78.23	
(iv) Other Financial Liabilities					
	26.39	28.99	26.39	28.99	
(b) Other Current Liabilities					
	245.81	180.13	253.53	183.41	
(c) Current tax liabilities(Net)					
	48.54	48.12	53.79	52.58	
(d) Provisions					
	110.07	110.07	110.07	110.07	
TOTAL - EQUITY AND LIABILITIES					
	13,666.85	12,607.45	13,136.96	12,079.03	

Saitan



Rs. in Lakhs

Cash Flow Statement

3	Particulars	Standalone		Consolidated	
		For the Half year ended 30th Sep 2023	For the Half year ended 30th Sep 2022	For the Half year ended 30th Sep 2023	For the Half year ended 30th Sep 2022
		Un-audited	Un-audited	Un-audited	Un-audited
A. Cash Flow From Operating Activities					
	Profit before Tax from continued business	(237.16)	925.16	(233.02)	885.97
	Adjustment for :				
	Finance Costs	257.89	191.92	257.89	191.92
	Depreciation and Amortization Expenses	320.04	333.92	320.14	334.00
	Sundry balances written off	8.98	2.48	8.98	2.48
	Net (Gain)/Loss on sale of Property ,Plant and Equipment	0.01	(2.24)	0.01	(2.24)
	Interest Income	(10.56)	(8.25)	(10.56)	(8.25)
	Gain on sale of Mutual Fund measured at fair value		(0.49)		(0.49)
	Gain on Lease Modification	(10.06)		(10.06)	
	Bad Debts written off		54.82		54.82
	Unspent liabilities written back	(51.41)	(8.27)	(51.41)	(210.34)
	Unrealised (gain)/loss foreign currency transactions and translation/FCTR	(20.64)	(85.41)	(38.61)	(42.41)
	Operating profit before working capital changes	257.09	1,403.64	243.36	1,205.46
	Changes in working Capital:				
	(Increase)/Decrease in Inventories	(345.88)	121.67	(350.70)	56.33
	(Increase)/Decrease in Trade and other Receivables	(959.70)	(948.79)	(1,001.89)	(659.23)
	Increase /(Decrease) in Trade and other payable	129.45	246.40	134.69	269.45
	Cash generation from Operation	(919.04)	822.92	(974.54)	872.01
	Payment/refund of Direct Taxes	0.42	(104.63)	0.63	(104.39)
	Net Cash generated/ (used) - Operating Activities	(918.62)	718.29	(973.91)	767.62
B. Cash Flow from Investing Activities					
	Purchase of Property, Plant and Equipment & Intangible Assets including CWIP	(91.71)	(341.58)	(91.71)	(341.58)
	Sale of Property, Plant and Equipment	-	23.70	-	23.70
	Sale of Mutual Funds	-	103.76	-	103.76
	Movement in Term Deposits	-	(115.67)	-	(115.67)
	Interest Received	3.23	19.59	3.23	19.65
	Net Cash Generated/ (Used) - Investing Activities	(88.48)	(310.20)	(88.48)	(310.14)
C. Cash Flow from Financing Activities					
	Receipts from Non Current Borrowings	250.00	370.50	250.00	370.50
	Repayment of Non Current Borrowings	836.60	(281.32)	836.60	(281.32)
	Loan repaid to Director	(66.50)	(91.00)	(66.50)	(91.00)
	Receipts/(Repayment) of Current Borrowings (Net)	234.24	(228.41)	234.24	(228.41)
	Payment of lease liability	(12.89)	(11.98)	(12.89)	(11.98)
	Finance Cost Paid	(234.16)	(167.96)	(234.16)	(167.96)
	Net Cash Generated/ (Used) - Financing Activities	1,007.29	(410.17)	1,007.29	(410.17)
	Net Increase/ (Decrease) in Cash and Cash Equivalents (A+B+C)	0.19	(2.08)	(55.10)	47.31
	Add : Opening Cash and Cash Equivalents	1.58	3.42	58.67	26.60
	Closing Cash and Cash Equivalents	1.77	1.34	3.57	73.91

- 4 These financials results have been prepared in accordance with the Indian Accounting Standards (Ind-AS) prescribed u/s 133 of the companies act, 2013 and other recognised accounting practises and policies to the extent applicable.
- 5 As the Company's business fall within a single primary business segment viz. sale of capsule, the disclosure requirement of Indian Accounting Standard (Ind AS-108) "Operating Segments" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder, is not applicable.
- 6 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on November 09, 2023 .

Place: NEW DELHI
Date: 09-11-2023



Anil Khaitan
(Chairman cum Managing Director)
DIN 00759951

Review Report on unaudited standalone quarterly and half yearly financial results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended

To the Board of Directors of Sunil Healthcare Limited

We have reviewed the accompanying statement of unaudited standalone financial results ("Statement") of Sunil Healthcare Limited ("the Company") for the quarter and half year ended September 30, 2023. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Noida (Delhi-NCR)
Date: November 09, 2023



For Singhi & Co.
Chartered Accountants
Firm Registration No. 302049E


Bimal Kumar Sipani
Partner

Membership No. 088926
UDIN: 23088926BGXBOQ6938

Independent Auditor's Review Report on consolidated unaudited quarterly and half yearly financial results of Sunil Healthcare Limited, Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended

To Board of Directors of Sunil Healthcare Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Sunil Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended September 30, 2023, ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities
 - a. Sunil Healthcare Mexico SA De CV (Incorporated in Mexico)
 - b. Sunil Healthcare North America LLC (Incorporated in USA)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement read with notes therein, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. The consolidated unaudited financial results include the interim financial results of two foreign subsidiaries whose financial statements are not required to review according to the law of respective countries and whose financial results reflect total assets of Rs. 473.93 Lakhs as at September 30, 2023 and total revenue from operation of Rs. 12.51 Lakhs and Rs. 34.66 Lakhs, loss after tax of Rs. 18.12 Lakhs and Rs. 26.69 Lakhs and total comprehensive income of (Rs. 16.54 Lakhs) and (Rs. 45.37 Lakhs) for the quarter and half year ended September 30, 2023 respectively, and net cash outflow of Rs. 55.29 Lakhs for the half year ended September 30, 2023 as considered in the Statement. According to the information and explanations given to us by the management, these Interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

Place: Noida (Delhi-NCR)

Date: November 09, 2023



For Singhi & Co.
Chartered Accountants
Firm Registration No. 302049E


Bimal Kumar Sipani
Partner

Membership No. 088926
UDIN: 23088926BGXBOR3528


Annexure-1

Name of Director & DIN	Dr. Harish Pal Kumar (DIN: 01826010)
Reason for change	Re-appointment as Non-executive & Independent Director of the Company for second term of 5 consecutive years (subject to approval via Special Resolution by Shareholders through postal ballot).
Date of Appointment	Re- 5 years from 13.02.2024 to 12.02.2029
Brief Profile	<p>Dr. Harish Pal Kumar has done Post Graduate in Commerce, a qualified Banker (C.A.I.I.B.), Fellow member of the Institute of Cost Accountant of India (ICAI) and has done PHD in employment creation through Rural Industrialization.</p> <p>He has a long career spanning more than four decades in finance, banking and MSME Sector. He has been the Chairman cum Managing Director of "The National Small Industries Corporation Ltd.", a public sector corporation of the Government of India for a period of 9 years until 2014 and has a rich experience in the promotion and development of Micro, Small and Medium Enterprises (MSME's) throughout the country.</p> <p>Dr. Kumar is the recipient of many awards from national and international fraternity including the coveted Silver Plate Award for CSR from the President of India. Major awards include India Pride Award from the Union Petroleum Minister, Govt. of India, in recognition for creation of new employment opportunities for unemployed youth, an international council of Arab League Award' comprising 22 countries in recognition of his outstanding contribution in the field of MSME sector in the region, Gold Medal at India Pride Award for excellence in creating impact in the Indian economy and Society etc.</p>
Disclosure of Relationship with Directors	Dr. Harish Pal Kumar is not related to any of the existing Directors of the company in any way.



Annexure-2

Name of Director & DIN	Mr. Bejon Kumar Misra (DIN: 01015633)
Reason for change	Re-appointment as Non-executive & Independent Director of the Company for second term of 5 consecutive years (subject to approval via Special Resolution by Shareholders through postal ballot).
Date of Appointment	Re- 5 years from 14.08.2024 to 13.08.2029
Brief Profile	<p>Mr. Bejon Misra had completed Degree from Senior Cambridge Board and subsequently Degree in Business Management with Marketing as major from Banaras Hindu University (BHU) in the year 1971.</p> <p>He has professional experience of around five decades, starting from Kolkata as a Marketing Executive with TATA Steel in the year 1971 and subsequently became an entrepreneur in Jamshedpur in the Travel Industry & Leasing Business. At present he is the 'Fellow' of Institute Of Directors (IOD), India, Adviser and Consultant to several Industry Associations and Business Entities; Founder Director of HAMARA CONSUMER DOST Pvt. Ltd., Consultant Consumer Affairs to Amway India Limited & Advisory Board Member of Global Healer LLC, USA & Alliance for Safe Online Pharmacies (ASOP) Global USA. Senior Expert with European Business & Technology Centre, New Delhi. He is having more than 25 years of experience as an International Expert on User (Consumer) Focus and more than 35 years of experience in the consumer education and advocacy. At present Mr. Misra is the Adviser to the Government of Odisha, Department of Food Supplies and Consumer Welfare (FS&CW), Chairman of the Core Group of Experts for Insurance Sector constituted by Ministry of Ayush, Government of India. Executive Committee (EC) Member of General Insurance Council nominated by IRDAI, Advisory Committee Member, in accordance with Rule 19 of the Insurance Ombudsman Rules, 2017. Consumer Guidance Society of Jamshedpur (CGSJ) is a Member of the Zonal Railway Users' Consultative Committee (ZRUCC), South Eastern Railway and also a Member of the Divisional Railway Users' Consultative Committee (DRUCC) Chakradharpur Division (CKP), South Eastern Railways. Professor (Research & Development) North East Christian University, Dimapur, Nagaland. Chairman, Food Safety & Consumer Protection Committee, North East Regional Council of the Indian Chamber of Commerce (ICC), Chair, Health Insurance Vision 2030 of the Federation of Telangana Chambers of Commerce and Industry (FTCCI) Hyderabad, Board Member, National Accreditation Board for Hospitals & Healthcare Providers (NABH-QCI). Member of the Ethics Committee of National Dope Testing Laboratory (NDTL), Ministry of Youth Affairs & Sports, Government of India. Expert Member of the Core Training Panel, National Coordination Center, Pharmacovigilance Program of India (NCC-PvPI), Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, Government of India. Printer, Publisher and Editor of THE AWARE CONSUMER, English Monthly Consumer Magazine published from Delhi and registered with RNI.</p>



	<p>Mr. Misra was the Former Visiting Professor to the Institute of Management (IM) BHU and Former Adviser/Consultant to Institute of Medical Sciences (IMS) BHU. Former Member of the Planning & Monitoring Board of JSS Academy of Higher Education & Research (JSSAHER), MYSURU. Visiting Professor of National Law University Odisha, Former Governing Board Member, Quality Council of India (QCI), Former Member of Food Safety and Standards Authority of India (FSSAI) from 2008-2013.</p>
<p>Disclosure of Relationship with Directors</p>	<p>Mr. Bejon Kumar Misra is not related to any of the existing Directors of the company in any way.</p>

